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GLUCOCORTICOSTEROIDS are the mainstay of treatment of
active  Crohn’s  disease  and  ulcerative  colitis.  These
drugs however carry important cosmetic short-term
side  effects  and  when  used  long-term  they  induce
severe  irreversible  complications.  Topically  acting
glucocorticosteroids,  especially  budesonide,  have
been  designed  to  achieve  local  effect  at  the  site  of
inflammation  without  systemic  effects  of  the  drug.
The first results of clinical trials are promising and
budesonide  has  been  shown  to  have  an  improved
safety  with  almost  comparable  efficacy  in  compar-
ison  with  prednisolone.  The  optimal  enema  dose
seems to be 2 mg/100 ml at night whereas 9 mg o.m. is
the  optimal  dose  to  treat  ileal  or  right  ileocolonic
Crohn’s disease. Topically acting GCS, like standard
GCS are not effective for maintenance of remission of
Crohn’s disease or recurrence prevention after resec-
tion of the involved Crohn’s segment.
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Introduction
A  glucocorticosteroid  can  have  a  selective  topical
action when the drug acts at the level of the mucosa
and  is  almost  not  absorbed.  Examples  are  pre-
dnisolone  metasulphobenzoate  and  hydrocortisone
foam. Other steroids are readily absorbed but undergo
a very rapid first pass metabolism resulting in very
low systemic blood levels. Examples are bethametha-
sone dipropionate, budesonide and fluticasone pro-
pionate. Tixocortol pivalate is characterized by low
absorption  and  high  first  pass. The  most  suitable
glucocorticoids  for  topical  therapy  are  budesonide
and fluticasone propionate.
The efficacy and safety of topical enema therapy
using  the  new  glucocorticosteroid  budesonide  in
distal  colitis  are  already  well  established.  Recent
developments  in  the  use  of  this  drug  for  peroral
therapy in Crohn’s disease is of great interest. Oral
formulations are also under study for the treatment of
ulcerative colitis. We will focus this review mainly on
the  use  of  topically  acting  glucocorticosteroids  in
Crohn’s disease.
In past years numerous attempts have been made
to  develop  glucocorticosteroids  with  high  topical
activity lacking the systemic activity of the drug and
hence carrying less side effects.
The  ideal  topically  acting  glucocorticosteroid
should have sufficient water solubility for a homoge-
neous  distribution  in  the  bowel  lumen.  A  high
uptake  rate  should  be  combined  with  sustained
binding at  the  level  of  the  target tissue  with  deep
penetration into the bowel wall. There should be a
high  affinity  for  the  steroid  receptor  and  high
intrinsic  activity  at  this  level.  Hepatic  first  pass
inactivation should be maximal. Candidate drugs are
budesonide, fluticasone propionate and beclometha-
sone dipropionate.
Budesonide, however, has the best profile since its
water solubility is 100 times higher than that of the
two latter drugs. Crohn’s disease is mostly located in
the ileocolonic region of the bowel whereas isolated
colonic disease occurs in about 30% of the patients
and isolated proximal small bowel disease is very rare.
Therefore formulations used should release the drug
at  the  very  site  of  the  diseased  bowel.  Entocort®
capsules release budesonide in a controlled manner in
the ileum resulting in an absorption of 52–79% in the
ileum  and  the  right  colon.1 The  drug  is  largely
metabolized on first pass through the liver resulting in
a bioavailability of 9–12% .  Preliminary studies indi-
cate  that  plasma  concentrations  in  patients  with
active Crohn’s disease might be higher than in normal
volunteers.2 The  influence  of  feeding  with  this
preparation on pharmacokinetics does not seem to be
important.
Budenofalk® (oral pH dependent release budeso-
nide) results in absorption of budesonide after 2–4h,
the rate being influenced by feeding in an important
manner. Measurements of excretion in ileostoma bags
showed  that  25–37%  of  the  budesonide  of  this
formulation enters the colon.3
0962-9351/98/030137-04 $9.00 © 1998 Carfax Publishing Ltd 137
Mini-Review
Mediators of Inflammation, 7, 137–140 (1998)Trials with Budesonide in Ileal and Right
Ileocolonic Crohn’s Disease
Open trial with entocort®
L¨ ofberg  et  al.4 studied  the  efficacy  and  safety  of
controlled ileal release budesonide in an open uncon-
trolled trial. Twenty-one patients with active Crohn’s
disease involving the distal ileum, the ileocaecal area
or the ascending colon entered the trial. The patients
received budesonide CIR in a dose of 3mg t.d.s. for 12
weeks, followed by tapering to 2mg t.d.s. for 6 weeks
and finally to 1mg t.d.s. for an additional 6 weeks.
Primary variables of efficacy were a modified Crohn’s
disease activity index (mCDAI), laboratory parameters
of  activity  and  plasma  cortisol  levels.  The  mean
mCDAI level at entry amounted to 268 (± 71 SD) and
decreased to 146 (± 91) at 4 weeks, 122 (± 87) at 12
weeks  (P <  0.001).  There  was  also  a  significant
decrease  of  ESR  during  the  study  period. Eighteen
patients  responded  favourably  during  the  first
12-week treatment period and 13 completed the trial.
No serious side effects occurred. The mean plasma
cortisol levels decreased but remained within normal
range. Four patients were markedly suppressed on the
highest dose of budesonide.
Controlled trials with entocort®
In a double-blind multicentre Canadian dose finding
trial5 258 patients were randomly assigned to receive
placebo or one of three doses of budesonide–39 or
15mg  daily. The  drugs  were  given  in  two  divided
doses in the morning and the evening. The primary
outcome measure was clinical remission as defined by
a score of 150 or less on the Crohn’s activity index.
Changes in the quality of life were also assessed with
an inflammatory bowel disease questionnaire. Serum
corticotropin stimulation tests were also performed.
After  8  weeks  of  treatment,  remission  occurred in
51% of the patients in the group receiving 9mg of
budesonide (95%  confidence interval, 39–63%), 43%
of  those receiving 15mg  (95% confidence  interval,
31–55%)  and  33%   of  those  receiving  3mg  (95%
confidence interval, 21–44%) compared with 20% of
those receiving placebo (P < 0.001, P = 0.009 and P
= 0.13 respectively). Improvements in the quality of
life  paralleled  these  remission  rates.  Location  of
disease, prior surgical resection, and previous use of
corticosteroids did not affect the outcome. Budeso-
nide  caused  a  dose-related  reduction  in  basal  and
corticotropin-stimulated  plasma  cortisol  concentra-
tions but was not associated with clinically important
corticosteroid-related  symptoms  or  other  toxic
effects.
A European multicentre study group conducted a
randomized  double-blind  10-week  trial6 comparing
the efficacy  and safety of an oral controlled-release
form of budesonide with the efficacy and safety of
prednisolone  in  176  patients  with  active  ileal  or
ileocaecal Crohn’s disease (88 patients in each treat-
ment group). The dose of budesonide was 9mg per
day for 8 weeks and then 6mg per day for 2 weeks.
The dose of prednisolone was 40mg per day for 2
weeks, after which it was gradually reduced to 5mg
per  day  during  the  last  week.  Again  the  primary
outcome parameter was the CDAI score with remis-
sion defined as a score of 150 or less. Three objective
parameters  of  inflammation  were  also  assessed
including ESR, C-reactive protein and orosomucoid.
At  10  weeks,  53%  of  the  patients  treated  with
budesonide were in remission compared with 66%  of
those treated with prednisolone (P = 0.12). The mean
score on the Crohn’s disease activity index decreased
from 275 to 175 in the budesonide group and from
279 to 136 in the prednisolone group (P = 0.001).
ESR,  CRP  and orosomucoid decreased more in the
prednisolone group than in the budesonide group but
the difference was significant only for ESR. Corticoste-
roid-associated  side-effects  were  significantly  less
common in the budesonide group (29 vs. 48 patients,
P = 0.003). Two patients in the prednisolone group
had serious complications (one had intestinal perfora-
tion and one an  abdominal  wall fistula). The mean
morning  plasma  cortisol  concentration  was  signifi-
cantly lower in the prednisolone group than in the
budesonide group after 4 weeks (P < 0.001) and 8
weeks  (P =  0.02)  of  therapy,  but  not  after  10
weeks.
An International Budesonide Study Group7 investi-
gated the efficacy and safety of two different dosage
regimens of budesonide, 9mg once daily (o.m.) in the
morning and 4.5mg twice daily in comparison with
prednisolone 40mg in one dose daily. In this multi-
centre trial 177 patients with active Crohn’s disease
(CDAI > 200) were randomly assigned to one of the
three treatments for 12 weeks. The budesonide dose
was tapered to 6mg after 2 weeks and to 3mg after 10
weeks.
Prednisolone was tapered to 30mg after 2 weeks
and then gradually to 5mg during the last 3 weeks.
Efficacy was measured based on remission rates, with
remission  being  defined  as  CDAI  £   150.  During
therapy  disease  activity  rapidly  decreased  in  all
groups. After 2 weeks the remission rate amounted to
48% in the budesonide (o.m.) compared with 37%  in
the prednisolone group. At 8 weeks similar remission
rates  were  observed  in the  budesonide  (o.m.)  and
prednisolone groups (both 60%) compared with 42%
in  the  budesonide  b.i.d.  group. The  proportion  of
patients  with  corticosteroid-associated  side-effects
was not significantly different in the three groups but
the  proportion  of  patients  with  moon  face  was
significantly higher in the prednisolone group. At 8
weeks  mean  morning  plasma  cortisol  levels  were
significantly  less  suppressed  in  both  budesonide
groups  than  in  the  prednisolone  group.  Impaired
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tion test was also significantly more common in the
prednisolone group than in the budesonide group.
Budenofalk
® versus 6-methylprednisolone
In this  study8 only 67 patients with active Crohn’s
disease  were  included.  Thirty-four  patients  were
treated with 3 3 3mg per day of budesonide and 33
with 6-methylprednisolone 48mg per day with taper-
ing. At eight weeks 55.9%  of the budesonide patients
achieved  remission  versus  72.7%  in  the  6-methyl-
prednisolone  group.  The  difference  was  not  sig-
nificant. There was a greater decrease, although not
significant, of the CDAI in the 6-methylprednisolone
group than in the budesonide group (BUD: 263 ± 50
to 118 ± 69; M-Pred: 262 ± 81 to 95 ± 61). Steroid
related side effects appeared in 28.6%  of the patients
in  the  budesonide  group  and  in  69.7%  in  the
6-methylprednisolone group (P = 0.0015).
Dose finding study with budenofalk
®
A recent dose finding study9 comparing three doses
of Budenofalk, 3 3 2mg, 3 3 3mg and 3 3 6mg in
active  Crohn’s  ileocolitis  yielded  remission  rates
(CDAI < 150) after six weeks of treatment in 36% , 55%
and 66% of the patients respectively. The mean CDAI
decreased from 257 ± 77 to 202 ± 103 in the 3 3 2mg
group, from 268 ± 75 to 140 ± 83 in the 3 3 3mg
group and from 239 ± 63 to 116 ± 57 in the 3 3 6mg
group.  Mean  basal  plasma  cortisol  levels  were
decreased by 21.7% (3 3 2mg), 48.7%  (3 3 3mg) and
59.4%  (3  3 6mg).  Glucocorticosteroid  associated
side effects occurred in 20% (3 3 2mg), 21% (3 3
3mg) and 31% (3 3 6mg) of the patients. Unfortu-
nately  in  this  study  no control  group  treated with
standard  glucocorticosteroids  was  included. There-
fore a comparison of the ratio efficacy to safety is not
possible.
Budesonide for Maintenance Therapy of
Crohn’s Disease
Entocort
® and prolongation of remission
During  a  1  year  follow-up  study  of  the  European
multicentre  trial6 90  patients  with  active  Crohn’s
disease in the terminal ileum of the ileocaecal area
who were in remission (CDAI-score £  150) after 10
weeks’ treatment with either oral Entocort® or oral
prednisolone, were randomized to receive continued
treatment with either Entocort® 6mg or 3mg daily, or
placebo for up to 1 year in order to prevent relapse.10
A relapse was  defined as  an increase  of  the  CDAI-
score above 150 points, and at least 60 points above
the  baseline,  or  deterioration  of  the  disease  that
required other treatment.
This  double-blind,  controlled,  randomized  trial
involved 11 centres in six European countries. The
6mg group had significantly longer median time to
relapse  or  discontinuation  of  treatment  compared
with the placebo group (258 vs. 92 days; P = 0.02). An
adrenocorticotropic hormone (ACTH)-test performed
after 3 months was normal in all 13 patients (100%)
remaining in the placebo group at this stage of the
study, compared with 19 out of 22 patients (86.4%) in
the Entocort® 3mg group, and 18 out of 23 patients
(78.3% ) in the Entocort® 6mg group. There were no
statistically significant differences between the three
treatment  groups.  Glucocorticosteroid-related  side
effects were mild (i.e. moon-face, acne) and mostly
related to previous prednisolone treatment.
A continuation of the Canadian multicentre study5
of Entocort® vs. placebo for active Crohn’s disease
was  designed  in  a  similar  way  to  the  European
maintenance trial. One hundred and five patients with
inactive  Crohn’s disease in the ileum  or ileum  and
proximal  colon  received  continued  treatment  with
either placebo or oral Entocort® 3 or 6mg daily in a
12-month, double-blind, randomized trial.11
The Entocort® 6mg group also fared better in this
study, with median time to relapse or discontinuation
of therapy of 178 days, vs. 124 days in the 3mg group,
and  39  days  among  placebo-treated  patients  (P =
0.026). However,  the  rate  of  relapse  did not  differ
significantly between the three treatment groups after
12 months of treatment; 61% of the patients in the
Entocort® 6mg treatment group had relapsed after 12
months, compared with 70%  in the Entocort® 3mg
treatment group and 67%  in the placebo group (P =
0.75). The relapse rates at 1 year were in agreement
with the results documented from the European study.
Basal  levels  of  plasma  cortisol  did  not  differ
between the three study groups during the trial. A
dose-dependent reduction in ACTH-stimulated corti-
sol concentration was found, but was not associated
with clinically important steroid-related side effects.
Budenofalk
® and maintenance of remission
Budenofalk  3  3 1mg/day is  not  more  effective  to
maintain remission of Crohn’s disease put into remis-
sion  with  glucocorticosteroids  than  placebo.12 The
proportion of patients in remission after 3, 6 and 12
months was  66% ,  44%   and 35% in the budesonide
group and 62% , 42% and 29% in the placebo group.
It  is  not  clear  why  maintenance  therapy  with
standard glucocorticosteroids and also with topically
acting  glucocorticosteroids including  budesonide  is
not effective. Down-regulation of glucocorticosteroid-
receptors might be a reason. Rogler et al.13 recently
reported  on  a  decrease  of  mucosal  intracellular
glucocorticoid  receptors  in  the  colonic  mucosa  in
patients with IBD independent from therapy, whereas
no decrease in systemic levels were observed.
Oral topically acting glucocorticosteroids in the treatment of IBD
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that patients chronically treated with standard gluco-
corticosteroids for Crohn’s disease successfully can be
switched  to  oral  pH-dependent  release  budesonide
(Budenofalk®) and that the success of the switch was
dose dependent, 9mg of budesonide being the most
effective dose. One can argue, however, that in that
manner  prednisolone  dependent  patients  become
budesonide dependent patients which presents only
borderline advantages in the long term. This condition
might better be managed by starting the patients on
immunosuppression.
Postoperative recurrence prophylaxis
In  a  study  comparing  budesonide  6mg/day  every
morning with placebo, the frequency of endoscopic
recurrence did not differ between the groups (intent-
to-treat analysis) at 3 months (45% vs. 46% ) or at 12
months (63% vs. 63% ).15 The recurrence rates were,
however, different with respect to the indication for
surgery. There was no difference between treatments
in patients who had undergone surgery for fibroste-
nosis,  whereas  endoscopic  recurrence  rates  were
lower in the budesonide treatment group, both at 3
months (21%  vs. 47%; P = 0.012) and at 12 months
(32%   vs.  65% ;  P =  0.048)  in  patients  who  had
undergone surgery for disease activity.
Budesonide for Induction of Remission in
Crohn’s Disease: Comparison with 5-ASA
In  a  pivotal-study  Thomsen  et  al.16 showed  that
budesonide  9mg  o.m.  (Entocort®)  is  significantly
more efficacious than mesalazine 2g b.i.d. to induce
remission  in  ileal  and  right  ileocolonic  Crohn’s
disease. Remission rates with budesonide were 44% ,
48%, 69% , 64% , 62%  after 2, 4, 8, 12 and 16 weeks
compared  with  37% ,  39% ,  45%,  42%   and  36%  for
mesalazine (P < 0.01 at 8, 12 and 16 weeks). Adverse
effects were similar in both groups. Twenty per cent
of  the  patients  in  the  budesonide  group  had
decreased adrenal function.
Conclusion
Budesonide  is  a  valuable  approach  for  developing
topical  therapy  of  IBD  with  glucocorticosteroids.
Entocort  releases  the  drug  more  proximally  and is
very  suitable  for  the  treatment  of  ileal  and  right
ileocolonic disease. Budenofalk releases more budeso-
nide in the colon and might be more suitable to treat
colonic disease although data are lacking. Budesonide
is as effective as standard glucocorticoids to induce
remission  in  ileal  and  right  ileocolonic  Crohn’s
disease with less side effects. One morning dose of
9mg  is  probably  the  optimal  dose  although  more
studies are necessary.
Prolonged  treatment  with  6mg  of  Entocort  pro-
longs  remission but  does  not  maintain  it  over  one
year. Therefore pulse therapy should be preferred.
The  exact  place  of  budesonide  in  the  clinical
management of Crohn’s disease and ulcerative colitis
has still to be defined.
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